Background/Aims: The relationship between multiple sclerosis (MS) and anemia has not been clarified sufficiently. In this retrospective, cross-sectional, case-control study we evaluated in MS patients: (1) prevalence of anemia relative to sex- and age-matched controls; (2) relationships between patients' demographic, clinical and drug-related characteristics and anemia; (3) effect of anemia on the risk of developing MS. Methods: 187 consecutive MS patients (51 males, mean age (±SD) 44.5 ± 10.7 years) and 200 controls (56 males, mean age 45.5 ± 12 years) were included in the study. Anemia was defined as hemoglobin <12 g/dl for females and <13 g/dl for males. Results: There was a significant difference in the prevalence of anemia between MS patients and controls (35 (18.7%) and 19 (9.5%), respectively, p = 0.009). We did not find any association between patients' characteristics and anemia. The occurrence of anemia increased more than twice the risk of developing MS (odds ratio: 2.19, 95% confidence interval 1.19-4.0). Conclusion: Our study showed a consistent association between anemia and MS.

Keywords:
Multiple sclerosis, Anemia, Prevalence
1.
Lassmann H, Brück W, Lucchinetti CF: The immunopathology of multiple sclerosis: an overview. Brain Pathol 2007;17:210-218.
2.
Sandyk R, Awerbuch GI: Vitamin B12 and its relationship to age of onset of multiple sclerosis. Int J Neurosci 1993;71:93-99.
3.
Ramagopalan SV, Dyment DA, Valdar W, et al: Autoimmune disease in families with multiple sclerosis: a population-based study. Lancet Neurol 2007;6:604-610.
4.
Edwards LJ, Constantinescu CS: A prospective study of conditions associated with multiple sclerosis in a cohort of 658 consecutive outpatients attending a multiple sclerosis clinic. Mult Scler 2004;10:575-581.
5.
Kocer B, Engur S, Ak F, et al: Serum vitamin B12, folate, and homocysteine levels and their association with clinical and electrophysiological parameters in multiple sclerosis. J Clin Neurosci 2009;16:399-403.
6.
Saeedi M, Forughipour M, Sasannezhad P, et al: Interferon-beta-1b induced autoimmune hemolytic anemia in a patient with MS: a case report. Iran Red Crescent Med J 2011;13:210-212.
7.
Nerrant E, Charif M, Ramay AS, et al: Hemolytic uremic syndrome: an unusual complication of interferon-β treatment in a MS patient. J Neurol 2013;260:1915-1916.
8.
Lysandropoulos AP, Benghiat F: Severe auto-immune hemolytic anemia in a fingolimod-treated multiple sclerosis patient. Mult Scler 2013;19:1551-1552.
9.
Larochelle C, Grand'maison F, Bernier GP, et al: Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in relapsing-remitting multiple sclerosis patients on high-dose interferon β. Mult Scler 2014;20:1783-1787.
10.
Midaglia L, Rodriguez Ruiz M, Muñoz-García D: Severe haematological complications during treatment with natalizumab. Mult Scler 2012;18:1644-1646.
11.
Alanoglu G, Kilbas S, Arslan C, et al: Autoimmune hemolytic anemia during interferon-beta-I b treatment for multiple sclerosis. Mult Scler 2007;13:683-685.
12.
Kingwell E, Koch M, Leung B, et al: Cardiotoxicity and other adverse events associated with mitoxantrone treatment for MS. Neurology 2010;74:1822-1826.
13.
Rieckmann P, O'Connor P, Francis GS, et al: Haematological effects of interferon-beta-1a (Rebif) therapy in multiple sclerosis. Drug Saf 2004;27:745-756.
14.
Aslam AK, Singh T: Aplastic anemia associated with interferon beta-1a. Am J Ther 2002;9:522-523.
15.
Rodrigo L, Hernández-Lahoz C, Fuentes D, et al: Prevalence of celiac disease in multiple sclerosis. BMC Neurol 2011;11:31.
16.
Pugliatti M, Sotgiu S, Solinas G, et al: Multiple sclerosis prevalence among Sardinians: further evidence against the latitude gradient theory. Neurol Sci 2001;22:163-165.
17.
Polman CH, Reingold SC, Banwell B, et al: Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011;69:292-302.
18.
Shaygannejad V, Ardestani PE, Ghasemi M, et al: Restless legs syndrome in Iranian multiple sclerosis patients: a case-control study. Int J Prev Med 2013;4(suppl 2):S189-S193.
19.
Mir-Reza S, Tabatabaeiyan M, Doosti R, et al: Is anemia a probable cause of fatigue in patients with multiple sclerosis? Iran J Neurol 2013;12:35-36.
20.
Weiss G, Goodnough LT: Anemia of chronic disease. N Engl J Med 2005;352:1011-1023.
21.
Nemeth E, Tuttle MS, Powelson J, et al: Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004;306:2090-2093.
22.
Johnson D, Bayele H, Johnston K, et al: Tumour necrosis factor alpha regulates iron transport and transporter expression in human intestinal epithelial cells. FEBS Lett 2004;573:195-201.
23.
Byrd TF, Horwitz MA: Regulation of transferrin receptor expression and ferritin content in human mononuclear phagocytes. Coordinate upregulation by iron transferrin and downregulation by interferon gamma. J Clin Invest 1993;91:969-976.
24.
Stephenson E, Nathoo N, Mahjoub Y, et al: Iron in multiple sclerosis: roles in neurodegeneration and repair. Nat Rev Neurol 2014;10:459-468.
25.
Kang JH, Chen YH, Lin HC: Comorbidities amongst patients with multiple sclerosis: a population-based controlled study. Eur J Neurol 2010;17:1215-1219.
26.
Mahad D, Lassmann H, Turnbull D: Review: Mitochondria and disease progression in multiple sclerosis. Neuropathol Appl Neurobiol 2008;34:577-589.
27.
Paling D, Golay X, Wheeler-Kingshott C, Kapoor R, Miller D: Energy failure in multiple sclerosis and its investigation using MR techniques. J Neurol 2011;258:2113-2127.
28.
Bartels C, Späte K, Krampe H, et al: Recombinant human erythropoietin: novel strategies for neuroprotective/neuro-regenerative treatment of multiple sclerosis. Ther Adv Neurol Disord 2008;1:193-206.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.